Thousands of women have filed a transvaginal mesh lawsuit against the manufacturers of the devices. The most recent settlement, which is approximately $40k per claimant, comes from the company Coloplast. Medtronic, one of the world’s largest medical device manufacturers, agreed to buy Covidien Plc in 2014 to compete with Johnson & Johnson and other medical device makers. In June, Medtronic announced that it had settled at least 11,500 cases related to its Covidien unit, which is responsible for manufacturing and selling the implants. In addition to the recent payout, the firm set aside $180 million in the form of pre-trial settlements for its co-defendants.
The U.S. Food and Drug Administration is slow to follow its international counterparts and is likely to take a long time to enact regulations regarding the products.
However, thousands of transvaginal mesh lawsuits have already been filed in federal and state courts, and more are expected to be filed in the coming years. The number of transvaginal mesh lawsuits filed worldwide will likely exceed 135,000 by the end of the year.
Despite the progress in settlements, thousands of transvaginal mesh lawsuits are still pending in federal and state courts. In September, the American Medical System and C.R. Bard publicly announced settlements and agreed to pay $188.7 million by March 2021. AMS and Coloplast, the second largest manufacturer in the West Virginia MDL, agreed to settle nearly all pending transvaginal mesh cases for $16 million.
Although the settlement is a significant step forward, many lawsuits remain.
The SEC recently issued a ruling against Medtronic and its parent company Covidien. The companies claim that the other medical device manufacturer, Covidien, was responsible for marketing the vaginal mesh devices, but this has not been confirmed. Several companies and manufacturers have settled lawsuits based on the same allegations.
In May, Boston Scientific and C.R. Bard publicly disclosed settlements with transvaginal mesh manufacturers. In April, a jury in the state of Massachusetts awarded $73 million to a woman who was diagnosed with urinary leakage. Among the other plaintiffs, was a woman who had to undergo surgery to fix the mesh after undergoing pelvic reconstruction due to complications with the mesh. She also suffered from a weakened immune system, which caused her to experience a loss of function in her kidneys.
Since the first Transvaginal Mesh lawsuit was filed, the company was liable for the resulting problems.
The FDA approved the device, but it was marketed by another company. The FDA has said that the company has been negligent in marketing the device. It should not have been able to approve a mesh implant without warning women of its side effects. A patient who is experiencing transvaginal mesh side effects should seek compensation from the manufacturer.
Two transvaginal mesh lawsuits were recently settled by Boston Scientific and C.R. Bard. While Boston Scientific has voluntarily agreed to pay out more than $600 million in settlements, the companies have not settled with the women who sued them. In addition to the millions of dollars that were paid to the women, the settlements resulted in settlements and verdicts. In the meantime, the lawsuits will continue to rise, despite the COVID-19 pandemic.
In July 2015, a jury in California decided in favor of a woman who had a bacterial infection from transvaginal mesh.
In July 2014, a jury found for the woman who sued C.R. Bard, who had undergone surgery with the Avaulta Plus vaginal mesh in 2007, it was discovered that the implant caused complications. In June of this year, a $27 million verdict was awarded to the woman who received the Avaulta Plus vaginal-mesh product.
The FDA’s ruling in July also ruled in favor of a woman’s lawsuit against Boston Scientific. The company’s alleged negligence and unreliability of the transvaginal mesh caused her to undergo invasive procedures and develop a bacterial infection. The jury’s decision has been certified as a class action by Judge Perell. While this is an important win for the woman who has already experienced complications after the implantation of the device.